China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...

Hutchmed (HCM) announces that the new drug application for the combination of Orpathys and Tagrisso for the treatment of patients with locally ...

Limited (HK:0013) has released an update.Don't Miss Our New Year's Offers:Discover the latest stocks recommended by top Wall ...

Hutchmed (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the billionaire and his flagship conglomerate look to ramp up capital and ...

Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment ...

But the yard should be small, limited to a narrow set of advanced technologies with military applications, while broader commercial trade and investment with China would continue. As the Biden ...

In a move designed to advance its pipeline and its “innovative medicines business,” Chinese biotech Hutchmed will ...

Hutchmed sells a 45% stake in SHPL for $608 million and focuses on advancing its cancer and immunology pipeline, including ...

The firm also announced that it was divesting most of its equity interest in Shanghai Hutchison Pharmaceuticals to invest in its own pipeline.

HUTCH has once again demonstrated its unwavering commitment to uplifting local communities through a new partnership with the Seva Vanitha Unit of the Sri Lanka Air Force. As part of this initiative, ...

BEIJING, Jan 3 (Reuters) - Shipments to China of foreign-branded smartphones, including Apple Inc's (AAPL.O), opens new tab iPhone, fell by 47.4% in November from a year earlier, according to data ...